Simon Bury Joins Selcia
News Jun 03, 2011
Commenting on the appointment, Simon Saxby, CEO of Selcia, said: “We are delighted to welcome Simon Bury to Selcia Discovery’s rapidly expanding team. We look forward to Simon helping us develop our integrated drug Discovery division, and accelerate our growth into this strategic area, complementing our other world leading contract research services”.
Simon has over 30 years of commercial experience within the life sciences industry, and brings with him a strong mix of technical, strategic and business development expertise. Simon was most recently Chief Commercial Officer for Cyprotex Discovery Ltd, where he was responsible for the company’s global sales and marketing activities. Prior to Cyprotex, Simon held senior business development roles at Shanghai ChemPartner, Scottish Biomedical Ltd, Pharmacopeia Inc, Hewlett-Packard and Zymark Ltd.
On joining Selcia, Simon Bury commented, “Selcia Discovery has established a fabulous reputation for delivering high quality integrated drug discovery services to the global pharmaceutical and biotechnology industry. I am very much looking forward to using my experience to further advance this business”.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019